Aldosterone Synthase Inhibition With Lorundrostat for Uncontrolled Hypertension: The Target-HTN Randomized Clinical Trial
Luke J Laffin,David Rodman,James M Luther,Anand Vaidya,Matthew R Weir,Natasa Rajicic,B T Slingsby,Steven E Nissen,Target-HTN Investigators,Richard Beasley,Matthew Budoff,George Carr,Michael Carroll,Jose Cevallos Yepez,Anil Chhabra,Frank Cole,Leonard Dunn,William Eaves,Valentine Ebuh,Roger Estevez,Glenn Gould,Matthew Hong,Bruce Iteld,Mahendra Jain,Charles Kemp,Christina Kennelly,Mark Kleiner,Mark Kutner,Luke Laffin,Joseph Lambert,Gilbert Ledesma,Keung Lee,John Lentz,Steven Lupovitch,James Luther,Lon Lynn,Obadias Marquez,Mobeen Mazhar,David Morin,Joel Neutel,Yaa Oppong,Merlin Osorio,Andres Patron,Walter Pharr,Mercedes Ponce de Leon,Lilia Rodriguez-Ables,Jeffrey Rosen,Issac Sachmechi,Ronald Surowitz,Larkin Wadsworth,Jeffrey Wayne,Zahid Zafar
DOI: https://doi.org/10.1001/jama.2023.16029
IF: 11.816
2023-09-26
JAMA
Abstract:Importance: Excess aldosterone production contributes to hypertension in both classical hyperaldosteronism and obesity-associated hypertension. Therapies that reduce aldosterone synthesis may lower blood pressure. Objective: To compare the safety and efficacy of lorundrostat, an aldosterone synthase inhibitor, with placebo, and characterize dose-dependent safety and efficacy to inform dose selection in future trials. Design, setting, and participants: Randomized, placebo-controlled, dose-ranging trial among adults with uncontrolled hypertension taking 2 or more antihypertensive medications. An initial cohort of 163 participants with suppressed plasma renin (plasma renin activity [PRA] ≤1.0 ng/mL/h) and elevated plasma aldosterone (≥1.0 ng/dL) were enrolled, with subsequent enrollment of 37 participants with PRA greater than 1.0 ng/mL/h. Interventions: Participants were randomized to placebo or 1 of 5 dosages of lorundrostat in the initial cohort (12.5 mg, 50 mg, or 100 mg once daily or 12.5 mg or 25 mg twice daily). In the second cohort, participants were randomized in a 1:6 ratio to placebo or lorundrostat, 100 mg once daily. Main outcomes and measures: The primary end point was change in automated office systolic blood pressure from baseline to study week 8. Results: Between July 2021 and June 2022, 200 participants were randomized, with final follow-up in September 2022. Following 8 weeks of treatment in participants with suppressed PRA, changes in office systolic blood pressure of -14.1, -13.2, -6.9, and -4.1 mm Hg were observed with 100 mg, 50 mg, and 12.5 mg once daily of lorundrostat and placebo, respectively. Observed reductions in systolic blood pressure in individuals receiving twice-daily doses of 25 mg and 12.5 mg of lorundrostat were -10.1 and -13.8 mm Hg, respectively. The least-squares mean difference between placebo and treatment in systolic blood pressure was -9.6 mm Hg (90% CI, -15.8 to -3.4 mm Hg; P = .01) for the 50-mg once-daily dose and -7.8 mm Hg (90% CI, -14.1 to -1.5 mm Hg; P = .04) for 100 mg daily. Among participants without suppressed PRA, 100 mg once daily of lorundrostat decreased systolic blood pressure by 11.4 mm Hg (SD, 2.5 mm Hg), which was similar to blood pressure reduction among participants with suppressed PRA receiving the same dose. Six participants had increases in serum potassium above 6.0 mmol/L that corrected with dose reduction or drug discontinuation. No instances of cortisol insufficiency occurred. Conclusions and relevance: Among individuals with uncontrolled hypertension, use of lorundrostat was effective at lowering blood pressure compared with placebo, which will require further confirmatory studies. Trial registration: ClinicalTrials.gov Identifier: NCT05001945.